Vanguard Group Inc Biomea Fusion, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BMEA
# of Institutions
100Shares Held
23.1MCall Options Held
1.08MPut Options Held
359K-
Heights Capital Management, Inc San Francisco, CA3.84MShares$6.14 Million1.84% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.57MShares$5.71 Million0.65% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$3.75 Million0.0% of portfolio
-
Aisling Capital Management LP New York, NY2.05MShares$3.28 Million1.02% of portfolio
-
Woodline Partners LP San Francisco, CA1.74MShares$2.79 Million0.02% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $46.9M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...